Advocate Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.3M Buy
394,831
+670
+0.2% +$17.8K 1.74% 13
2026
Q2
$9.49M Buy
394,161
+39,109
+11% +$1.02M 1.43% 26
2026
Q1
$10M Buy
355,052
+6,553
+2% +$174K 1.56% 19
2025
Q4
$8.68M Sell
348,499
-1,531
-0.4% -$38.6K 1.4% 28
2025
Q3
$8.92M Buy
350,030
+4,655
+1% +$115K 1.47% 21
2025
Q2
$8.37M Sell
345,375
-8,297
-2% -$193K 1.5% 23
2025
Q1
$8.96M Buy
353,672
+12,294
+4% +$322K 1.63% 20
2024
Q4
$9.06M Buy
341,378
+12,548
+4% +$340K 1.71% 16
2024
Q3
$9.5M Buy
328,830
+11,989
+4% +$350K 1.73% 12
2024
Q2
$8.87M Buy
316,841
+21,772
+7% +$599K 1.79% 14
2024
Q1
$8.19M Buy
295,069
+59,561
+25% +$1.65M 1.63% 17
2023
Q4
$6.78M Buy
235,508
+10,548
+5% +$319K 1.46% 23
2023
Q3
$7.46M Buy
224,960
+5,433
+2% +$192K 1.73% 14
2023
Q2
$8.05M Buy
219,527
+12,315
+6% +$479K 1.77% 16
2023
Q1
$8.45M Buy
207,212
+9,214
+5% +$398K 1.85% 15
2022
Q4
$10.1M Buy
197,998
+4,756
+2% +$228K 2.18% 6
2022
Q3
$8.46M Buy
193,242
+2,007
+1% +$97.5K 2.09% 10
2022
Q2
$10M Buy
+191,235
New +$9.7M 2.33% 7

Other funds holding PFE

Advocate Group's PFE Position: Q3 2026 in Review

Advocate Group increased its Pfizer (PFE) stake by 0.17% in Q3 2026, buying an estimated $17.8K and bringing the position to 394,831 shares worth $11.3M. The position accounts for 1.74% of the portfolio, ranked #13.

Advocate Group first reported a position in PFE in Q2 2022 and has held it in 18 quarters since. 1,347 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Advocate Group held 394,831 shares of Pfizer worth $11.3M as of Q3 2026.
  • Advocate Group bought 670 Pfizer shares in Q3 2026, an estimated $17.8K.
  • Pfizer made up 1.74% of Advocate Group's portfolio in Q3 2026, its #13 holding.
  • Advocate Group first reported a position in Pfizer in Q2 2022 and has held it in 18 quarters since.
  • 1,347 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Advocate Group's 13F filing for Q3 2026, filed 19 Oct 2026.